Comparative Pharmacology
Head-to-head clinical analysis: FOSAMAX versus ZOMETA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSAMAX versus ZOMETA.
FOSAMAX vs ZOMETA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and impairing osteoclast activity through inhibition of farnesyl pyrophosphate synthase.
Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), thereby preventing the prenylation of small GTPase signaling proteins essential for osteoclast activity.
70 mg orally once weekly for osteoporosis; 10 mg orally once daily for Paget's disease.
4 mg IV over 15 minutes every 3-4 weeks for hypercalcemia of malignancy or bone metastases.
None Documented
None Documented
Terminal elimination half-life is approximately 10.5 years in bone, reflecting slow release from the skeleton. Plasma half-life after intravenous administration is about 1 hour.
Terminal elimination half-life is approximately 146 hours (6.1 days) due to prolonged release from bone; clinical context: supports monthly dosing for osteoporosis and quarterly for Paget's disease.
Renal excretion of unchanged drug is the primary route (approximately 50% of absorbed dose). Unabsorbed drug is eliminated in feces. No biliary excretion.
Renal: 50-60% of the dose excreted unchanged in urine within 24 hours; terminal elimination involves slow release from bone with subsequent renal excretion; biliary/fecal excretion is minimal (<5%).
Category C
Category C
Bisphosphonate
Bisphosphonate